Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Until platform closure (22)
Poster categories
  • Thematic Poster Session (24)
keywords
Session Reference
  • L-TPS01 (10)
  • L-TPS02 (13)
  • L-TPS03 (5)
  • L-TPS04 (12)
  • L-TPS05 (10)
  • L-TPS06 (7)
  • L-TPS07 (8)
  • L-TPS08 (7)
  • L-TPS09 (10)
  • L-TPS10 (10)
  • L-TPS11 (10)
  • L-TPS12 (8)
  • L-TPS13 (8)
  • L-TPS14 (11)
  • L-TPS15 (6)
  • L-TPS16 (7)
  • L-TPS17 (9)
  • L-TPS18 (9)
  • L-TPS19 (6)
  • L-TPS20 (7)
  • L-TPS21 (7)
  • L-TPS22 (9)
  • L-TPS23 (13)
  • L-TPS24 (10)
  • L-TPS25 (2)
  • TPS01 (9)
  • TPS02 (10)
  • TPS03 (6)
  • TPS04 (6)
  • TPS05 (10)
  • TPS06 (10)
  • TPS07 (6)
  • TPS08 (12)
  • TPS09 (12)
  • TPS10 (5)
  • TPS11 (6)
  • TPS12 (6)
  • TPS13 (10)
  • TPS14 (6)
  • TPS15 (4)
  • TPS16 (9)
  • TPS17 (8)
  • TPS18 (9)
  • TPS19 (9)
  • TPS20 (8)
  • TPS21 (10)
  • TPS22 (7)
  • TPS23 (8)
  • TPS24 (8)
  • TPS25 (5)
  • TPS26 (9)
  • TPS27 (12)
  • TPS28 (4)
  • TPS29 (5)
  • TPS30 (10)
  • TPS31 (5)
  • TPS32 (12)
  • TPS33 (12)
  • TPS34 (10)
  • TPS35 (7)
  • TPS36 (8)
  • TPS37 (10)
  • TPS38 (8)
  • TPS39 (10)
  • TPS40 (4)
  • TPS41 (10)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (9)
  • TPS45 (10)
  • TPS46 (6)
  • x TPS47 (11)
  • TPS48 (7)
  • TPS49 (10)
  • TPS50 (5)
  • TPS51 (2)
  • x TPS52 (8)
  • TPS53 (6)
  • TPS54 (8)
  • TPS55 (7)
  • TPS56 (10)
  • TPS57 (4)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (7)
  • TPS62 (10)
  • TPS63 (10)
  • TPS64 (12)
  • TPS65 (13)
  • TPS66 (7)
  • TPS67 (10)
  • x TPS68 (5)
  • TPS69 (11)
  • TPS70 (8)
  • TPS71 (8)
  • TPS72 (10)
  • TPS73 (9)
  • TPS74 (8)
  • TPS75 (7)
  • TPS76 (9)
  • TPS77 (6)
  • TPS78 (12)
  • TPS79 (2)
  • TPS80 (8)
  • TPS81 (6)
  • TPS82 (5)
  • TPS83 (4)
  • TPS84 (7)
  • TPS85 (8)
  • TPS86 (11)
  • TPS87 (7)
  • TPS88 (8)
  • TPS89 (4)
  • TPS90 (4)
  • TPS91 (3)
24 results
Thumbnail

D2.350 - Exploring the Psychological Burden of Hereditary Angioedema Using the Pictorial Representation of Illness and Self Measure (PRISM): Updated Insights from a Prospective Real-Life Cohort

Thumbnail

D2.351 - Germline Variant in the GNAI2 Gene Associated with Severe Immune Dysregulation and Autoimmune Hemolytic Anemia in a Pediatric Patient

Thumbnail

D2.352 - Epidermodysplasia verruciformis as a sign for STK4 deficiency

Thumbnail

D2.353 - Same Disease, Different Clinical Phenotypes: A20 Haploinsufficiency

Thumbnail

D2.354 - Evaluation of Subjective Sleep Quality and Psychological Status in Adult Patients with Inborn Errors of Immunity

Thumbnail

D2.362 - Clinical and Immunological Characteristics of Non-Infectious Complications in Common Variable Immunodeficiency: A Single-Center Retrospective Evaluation in Adult Patients with CVID

Thumbnail

D2.363 - Immunologic Basis of Coexisting Slowly Progressive Insulin-Dependent Diabetes Mellitus (SPIDDM) and Generalized Myasthenia Gravis (MG)

Thumbnail

D2.349 - RAPIDe‑3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks

Thumbnail

D2.357 - Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat

Thumbnail

D2.360 - Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat

Thumbnail

D2.361 - Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use

Thumbnail

D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD

Thumbnail

D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?

Thumbnail

D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets

Thumbnail

D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management

Thumbnail

D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM